{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:58:54Z","timestamp":1759514334947,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Transcatheter closure is now the preferred treatment for congenital heart disease complicated with pulmonary arterial hypertension (CHD-PAH), but its long-term effects are not well understood. We aimed to assess the safety, effectiveness, and outcome of this procedure in children with CHD-PAH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 210 children with CHD-PAH at our hospital from 2012 to 2021 and collected their general, laboratory, echocardiographic, and hemodynamic data for analysis. A logistic regression analysis identified risk factors for persistent postclosure PAH (PP-PAH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 210 patients, 84.29% had mild PAH, 8.57% had moderate PAH, and 7.14% had severe PAH. The device was successfully implanted in 98.10% of patients. Early adverse events occurred in 12.14% (<jats:italic>n<\/jats:italic>\u2009=\u200925) of patients, with residual shunts and arrhythmia being the most common complications, each affecting 2.91% (<jats:italic>n<\/jats:italic>\u2009=\u20096) of patients. Most complications were minor and temporary, except for two cases of residual shunt\u2014one required surgical repair, and one case of complete left bundle branch block led to occluder removal. Postintervention, pulmonary arterial pressure (PAP) decreased significantly, and cardiomegaly resolved. PP-PAH was detected in 13 patients (6.31%). Preoperative pulmonary arterial systolic pressure [odds ratio [OR]\u2009=\u20091.033, 95% confidence interval [CI]\u2009=\u20091.005\u20131.061, <jats:italic>P<\/jats:italic>\u2009=\u20090.019] and right ventricular diameter (OR\u2009=\u20091.111, 95% CI\u2009=\u20091.039\u20131.187, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) were found to be risk factors for PP-PAH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Transcatheter closure is effective and safe for children with correctable CHD-PAH. Preoperative pulmonary arterial systolic pressure and right ventricular diameter are risk factors for PP-PAH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1562782","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:51:26Z","timestamp":1741330286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Follow-up of transcatheter closure of congenital heart disease complicated with pulmonary arterial hypertension in children"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanyun","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingbing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piaoliu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.jacc.2011.08.025","article-title":"Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis","volume":"58","author":"van der Linde","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s11906-013-0397-5","article-title":"Epidemiology of pulmonary arterial hypertension","volume":"15","author":"Jiang","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/eurheartj\/ehx034","article-title":"Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease","volume":"38","author":"van der Feen","year":"2017","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jacc.2006.09.049","article-title":"Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease","volume":"49","author":"L\u00e9vy","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/eurheartj\/eht072","article-title":"Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups","volume":"35","author":"Manes","year":"2014","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","article-title":"2020 ESC guidelines for the management of adult congenital heart disease","volume":"42","author":"Baumgartner","year":"2021","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","article-title":"2019 Updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European pediatric pulmonary vascular disease network (EPPVDN), endorsed by AEPC, ESPR and ISHLT","volume":"38","author":"Hansmann","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3390\/jcm12072540","article-title":"Outcomes in patients with pulmonary arterial hypertension underwent transcatheter closure of an atrial septal defect","volume":"12","author":"Seol","year":"2023","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00380-011-0187-4","article-title":"The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension","volume":"27","author":"Huang","year":"2012","journal-title":"Heart Vessels"},{"key":"B10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.14503\/thij-19-6982","article-title":"Safety and outcomes of transcatheter closure of patent ductus arteriosus in children with pulmonary artery hypertension","volume":"47","author":"Salavitabar","year":"2020","journal-title":"Tex Heart Inst J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"693414","DOI":"10.3389\/fcvm.2021.693414","article-title":"Post-interventional evaluation and follow-up in children with patent ductus arteriosus complicated with moderate to severe pulmonary arterial hypertension: a retrospective study","volume":"8","author":"Rong","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/circinterventions.113.001135","article-title":"Trial occlusion to assess the risk of persistent pulmonary arterial hypertension after closure of a large patent ductus arteriosus in adolescents and adults with elevated pulmonary artery pressure","volume":"7","author":"Zhang","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.hlc.2010.08.010","article-title":"Progressive pulmonary hypertension post atrial septal defect device closure-early symptomatic improvement may not predict outcome","volume":"19","author":"O'Donnell","year":"2010","journal-title":"Heart Lung Circ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijcard.2019.12.070","article-title":"Pulmonary hypertension after shunt closure in patients with simple congenital heart defects","volume":"308","author":"Lammers","year":"2020","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"40s","DOI":"10.1016\/j.jacc.2004.02.032","article-title":"Diagnosis and differential assessment of pulmonary arterial hypertension","volume":"43","author":"Barst","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijcha.2016.05.012","article-title":"Pulmonary hypertension: prevalence and risk factors","volume":"11","author":"Faqih","year":"2016","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1017\/s1047951115002772","article-title":"Intermediate- and long-term follow-up of device closure of patent arterial duct with severe pulmonary hypertension: factors predicting outcome","volume":"27","author":"Sadiq","year":"2017","journal-title":"Cardiol Young"},{"key":"B20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.33963\/kp.15708","article-title":"Recent achievements in transcatheter closure of ventricular septal defects: a systematic review of literature and a meta-analysis","volume":"79","author":"Wery\u0144ski","year":"2021","journal-title":"Kardiol Pol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12872-019-1188-y","article-title":"Short- and medium-term follow-up of transcatheter closure of perimembranous ventricular septal defects","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fped.2018.00128","article-title":"Long-term outcome of transcatheter device closure of perimembranous ventricular septal defects","volume":"6","author":"Mandal","year":"2018","journal-title":"Front Pediatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5334\/gh.831","article-title":"Survival of left-to-right shunt repair in children with pulmonary arterial hypertension at a tertiary hospital in a low-to-middle-income country","volume":"16","author":"Arafuri","year":"2021","journal-title":"Glob Heart"},{"key":"B24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1017\/s1047951114000183","article-title":"Closure of large patent ductus arteriosus using the amplatzer septal occluder","volume":"25","author":"Garc\u00eda-Montes","year":"2015","journal-title":"Cardiol Young"},{"key":"B25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jacc.2004.03.074","article-title":"Multicenter USA amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results","volume":"44","author":"Pass","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.amjcard.2015.12.036","article-title":"Effectiveness and safety of transcatheter closure of perimembranous ventricular septal defects in adults","volume":"117","author":"Wang","year":"2016","journal-title":"Am J Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1136\/heartjnl-2019-316148","article-title":"Cardiac catheter intervention complexity and safety outcomes in adult congenital heart disease","volume":"106","author":"Brida","year":"2020","journal-title":"Heart"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jacc.2007.03.068","article-title":"Transcatheter closure of perimembranous ventricular septal defects: early and long-term results","volume":"50","author":"Butera","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1253\/circj.cj-13-1263","article-title":"Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease","volume":"78","author":"Myers","year":"2014","journal-title":"Circ J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/heartjnl-2018-314025","article-title":"Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease","volume":"105","author":"van der Feen","year":"2019","journal-title":"Heart"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jacc.2015.06.1318","article-title":"Lifetime risk of pulmonary hypertension for all patients after shunt closure","volume":"66","author":"van Riel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.echo.2013.10.014","article-title":"Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension","volume":"27","author":"Jone","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.amjcard.2010.10.027","article-title":"Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension","volume":"107","author":"Ghio","year":"2011","journal-title":"Am J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e00080","DOI":"10.1161\/hhf.0000000000000080","article-title":"Pulmonary hypertension in congenital heart disease: a scientific statement from the American heart association","volume":"16","author":"Jone","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.hfc.2018.03.011","article-title":"Right heart catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues","volume":"14","author":"D'Alto","year":"2018","journal-title":"Heart Fail Clin"},{"key":"B37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/circinterventions.108.826560","article-title":"Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study","volume":"2","author":"Yong","year":"2009","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1562782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T06:51:28Z","timestamp":1741330288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1562782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":37,"alternative-id":["10.3389\/fped.2025.1562782"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1562782","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"article-number":"1562782"}}